Recombinant Human C-Jun-Amino-Terminal Kinase-Interacting Protein 4 (SPAG9) Protein (His&Myc)

Name: Recombinant Human C-Jun-Amino-Terminal Kinase-Interacting Protein 4 (SPAG9) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-00223P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human C-Jun-Amino-Terminal Kinase-Interacting Protein 4 (SPAG9) Protein (His&Myc) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Activity	Not tested.
Uniprotkb	O60271
Target Symbol	SPAG9
Synonyms	(JIP-4)(JNK-interacting protein 4)(Cancer/testis antigen 89)(CT89)(Human lung cancer oncogene 6 protein)(HLC-6)(JNK-associated leucine-zipper protein)(JLP)(Mitogen-activated protein kinase 8-interacting protein 4)(Proliferation-inducing protein 6)(Protein highly expressed in testis)(PHET)(Sperm surface protein)(Sperm-associated antigen 9)(Sperm-specific protein)(Sunday driver 1)
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His&C-Myc
Target Protein Sequence	REVENLILENTQLLETKNALNIVKNDLIAKVDELTCEKDVLQGELEAVKQAKLKLEEKNRELEEELRKARAEAEDARQKAKDDDDSDIPTAQRKRFTRVEMARVLMERNQYKERLMELQEAVRWTEM
Expression Range	408-534aa
Protein Length	Partial
Mol. Weight	20.0 kDa
Research Area	Developmental Biology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. Regulates lysosomal positioning by acting as an adapter protein which links PIP4P1-positive lysosomes to the dynein-dynactin complex. Assists PIKFYVE selective functionality in microtubule-based endosome-to-TGN trafficking.
Subcellular Location	Cytoplasm. Cytoplasm, perinuclear region. Lysosome membrane.; [Isoform 5]: Cytoplasmic vesicle, secretory vesicle, acrosome.
Protein Families	JIP scaffold family
Database References	HGNC: 14524 OMIM: 605430 KEGG: hsa:9043 STRING: 9606.ENSP00000262013 UniGene: PMID: 29480665 Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer PMID: 27655714 SPAG9 mRNA and protein overexpression in lung cancer tissue, and the presence of SPAG9 IgG antibody in peripheral blood of lung cancer patients indicates that it has potential as a biomarker for lung cancer diagnosis. PMID: 26934841 SPAG9-elevated expression contributes to malignant behavior and poor prognosis of breast cancer and may support a potential indicator in treatment selection. PMID: 26631164 Study suggest that suppression of miR-141 may cause an aberrant overexpression of SPAG9 promoting growth and metastasis of hepatocellular carcinoma cells. PMID: 26790956 expression of SPAG9 in ECC cells with TGF-beta1 treatment and spheroids formation was increased PMID: 27352556 PLK1 binding to JIP4 was found in G2 phase and mitosis, and PLK1 binding was self-primed by PLK1 phosphorylation of JIP4. PMID: 26291670 Based on in vitro assays, we found miR-200a-3p significantly inhibit cancer cell proliferation by inducing apoptosis. PMID: 26797273 FOXK1 protein levels and activity are regulated by associating with JLP and PLK1 PMID: 26468278 SPAG9 overexpression in gastric cancer correlates with poor prognosis and contributes to gastric cancer cell proliferation PMID: 26293216 SPAG9 was upregulated in nonmelanoma skin cancer when compared with normal skin. PMID: 25033008 SPAG9 expression is significantly increased in prostate cancer and it may be involved in the process of prostate cancer cell motility, migration and angiogenesis. PMID: 25310386 knockdown of Sec8 enhances the binding of JIP4 to MAPK kinase 4, thereby decreasing the phosphorylation of MAPK kinase 4, JNK, and p38. PMID: 25244576 SPAG9 upregulates PODXL expression in human astrocytoma cells at the PODXL gene promoter/transcriptional level through a JNKdependent mechanism. PMID: 24788963 SPAG9 is overexpressed in human HCC and serves as a prognostic marker. SPAG9 contributes to cancer cell growth through regulation of cyclin proteins. PMID: 24801907 SPAG9 is overexpressed in human prostate cancers and contributes to prostate cancer cell growth, possibly through cyclin protein regulation. PMID: 24740566 down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells, suggesting that SPAG9 may be a potential target for therapeutic use. PMID: 24330581 data in clinical specimens indicated that SPAG9 is potential biomarker and therapeutic target for bladder TCC. PMID: 24349057 High SPAG9 expression is associated with endometrial cancer. PMID: 24460345 SPAG9 depletion could inhibit the activity of p-JNK. PMID: 23711689 SPAG9 serves as an important oncoprotein in human astrocytoma by regulating cell proliferation and invasion. PMID: 23696027 SPAG9 is positively expressed in endometrial cancer, and with a high humoral immune response in patients. It may serve as a new type of endometrial cancer markers for early detection, diagnosis and treatment. PMID: 22146769 These findings collectively suggest that SPAG9 may have a role in tumor development and early spread. PMID: 21356354 N-cadherin expression had an inhibitory effect on JLP-mediated p38 MAPK signal activation by decreasing the interaction between JLP and p38 MAPK PMID: 21177868 SPAG9 mRNA& protein are expressed in CML patients (88%) and in K562 & KCL-22 cells. 90% CML chronic-phase patients showed humoral response against SPAG9. PMID: 20138665 SPAG9 protein is found in the equatorial plate and flagella of human spermatozoa. PMID: 19947555 Testicular antigen PHET is an auutoantigen recognized by sera from systemic sclerosis (SSc) patients with extensive fibrotic changes; the autoantibody response to PHET is induced by ectopic overexpression of PHET in dermal fibroblasts of SSc patients. PMID: 14662895 first report of sperm-associated JNK-binding protein (SPAG9) that may have a role in spermatozoa-egg interaction PMID: 15693750 SPAG9 is a new member of c-Jun NH2 -terminal kinase (JNK) interacting protein exclusively expressed in testis PMID: 16077255 The present investigation will eventually extend the application of SPAG9 siRNA in in vivo targeting experiments that aim to define the SPAG9 functional genomics in tumor and reproductive biology. PMID: 16356479 Recombinant human protein is adsorbed on alum is highly immunogenic in macaca model and therefore represents a suitable sperm-based vaccine immunogen for fertility trials in macaque. PMID: 16959808 SPAG9 may have a role in tumor development and metastasis and thus could serve as a novel target for early detection and treatment of renal cell carcinoma. PMID: 18922895 Kinesin adapter JLP links PIKfyve to microtubule-based endosome-to-trans-Golgi network traffic of furin. PMID: 19056739 structural analysis of ARF6 in a complex with JIP4 PMID: 19644450 Findings support a potential role for SPAG9 as diagnostic biomarker as well as a possible therapeutic target in thyroid cancer treatment. PMID: 19820019

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.